TPG Dumped Opioid Co. On 'Unsuspecting' Endo, Suit Says
By Lauren Berg · August 19, 2024, 11:50 PM EDT
After pushing Par Pharmaceutical to grow its market share in generic opioids and disregard federal requirements to report suspicious orders, TPG Capital saw other opioid manufacturers being inundated with litigation and...
To view the full article, register now.
Try a seven day FREE Trial
Already a subscriber? Click here to login